




Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study

Yuzhong Cui^{1,2,3,4,5} · Wei Huang^{6,7} · Feng Du⁵ · Xiaoyang Yin^{6,7} · Lei Feng^{6,7} · Baosheng Li^{6,7} 

Published online: 6 December 2022
© The Author(s) 2022

Correction to: Clinical and Translational Oncology (2022) 24:1643–1656
<https://doi.org/10.1007/s12094-022-02818-7>

Following publication of this article, errors were identified in Fig. 4; specifically:

- Fig. 4-2B: in the immunofluorescence of K150-BCL2-24H, the following images were originally duplicated in error:
 - Combination (second row)
 - Niraparib Tosylate (3rd row)

- Fig. 4-2C: in the immunofluorescence of K30- γ H2AX(24H), the following image was originally duplicated in error:

– Radiation (1st row)

The images have been replaced with the correct images from the raw data.

The corrections do not have any effect on the final conclusions of the paper. The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s12094-022-02818-7>.

✉ Baosheng Li
bsli@sdfmu.edu.cn

¹ Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

² National Clinical Research Center for Cancer, Tianjin 300060, China

³ Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

⁴ Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

⁵ Department of Oncology, Zibo Municipal Hospital, Zibo 255400, China

⁶ Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China

⁷ Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyuan Road, Huaiyin District, Jinan 250117, Shandong, China

2








Figure 4 (2) **A** Immunofluorescence of γ H2AX. **B** Immunofluorescence of BAX. **C** Immunofluorescence of BCL-2. (3) mRNA relative expression level among the four groups for **A** KYSE-30 cell line. **B** KYSE-150 cell line. * $P < 0.05$, ** $P < 0.01$

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes

were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.